Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tourmaline Bio

Explore full profile

Developing transformative medicines that dramatically improve the lives of patients with life-altering immune diseases

New York City, United StatesFounded 2022Biotech & Life Sciences
Valuation $991M Market cap · 2025
Total funding $100–500M Disclosed equity funding

About Tourmaline Bio

Tourmaline Bio is a biotechnology company focused on developing transformative medicines aimed at dramatically improving the lives of patients with life-altering immune diseases. The company operates in the biopharmaceutical market, targeting rare and significant unmet medical needs. Tourmaline Bio serves patients suffering from severe immune disorders, working closely with healthcare providers and research institutions. Their business model revolves around the research, development, and commercialization of innovative therapies. Revenue is generated through the successful development and approval of these therapies, followed by their commercialization either directly or through partnerships with larger pharmaceutical companies.

Source: Dealroom company data

At a glance

Founded
2022
Headquarters
New York City, United States
Listing
IPO 2023
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tier

Research & analysis

From the Dealroom knowledge graph
Market map Rare Disease Therapeutics & Technologies Landscape

Latest news

Press, funding announcements and product moves mentioning Tourmaline Bio.

See all news

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • QVT Financial LP
  • Hydra Ventures
  • Petrichor

Series A3 investors entered at this stage

  • TCGX
  • Deep Track Capital
  • Cowen Healthcare Investments

Series B and later10 investors entered at this stage

  • Paradigm BioCapital
  • RA Capital Management
  • Great Point Partners
  • Acuta Capital Partners
  • Qiming Venture Partners USA
  • Braidwell
  • Affinity Asset Advisors
  • StemPoint Capital
  • KVP Capital
  • Vivo Capital

Talent

Book a demo to see the people
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
2.7K monthly visits
across markets
🇺🇸 United States74.1%
🇮🇳 India25.9%
Top 2 markets shown

Patents

Estimated portfolio value
$3M

6 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tourmaline Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tourmaline Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles